Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 102 pages | ID: NA77E2B7D40AEN
Global Markets Direct

Abstracts

Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia – Drugs In Development, 2022, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 7, 6 and 13 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Neutropenia – Overview
Neutropenia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neutropenia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neutropenia – Companies Involved in Therapeutics Development
Neutropenia – Drug Profiles
Neutropenia – Dormant Projects
Neutropenia – Discontinued Products
Neutropenia – Product Development Milestones
Featured News & Press Releases
Mar 29, 2022: EMA recommends granting a marketing authorisation for stimufend
Dec 08, 2021: Emendo Biotherapeutics to present new data at 63rd ASH Annual Meeting & Exhibition
Dec 02, 2021: X4 Pharmaceuticals to host virtual seminar “Understanding Primary Immunodeficiencies” to highlight broadening market opportunities for mavorixafor
Aug 03, 2021: X4 Pharmaceuticals announces key enrollment milestone achievements in ongoing mavorixafor clinical trials and reports second quarter financial results
Oct 12, 2020: BeyondSpring forms partnership advisory committee comprised of industry veterans
Sep 29, 2020: JAMA Oncology highlights plinabulin's efficacy in preventing chemotherapy-induced neutropenia as a monotherapy
May 27, 2020: FDA accepts for review Fresenius Kabi’s first biosimilar regulatory submission for MSB11455, a biosimilar candidate of pegfilgrastim
May 22, 2020: Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA
Apr 28, 2020: Mylan and Biocon launch Fulphila, Biosimilar Pegfilgrastim, in Canada
Apr 14, 2020: Biocon and Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Australia
Nov 05, 2019: X4 Pharmaceuticals initiates phase 1b clinical trial of Mavorixafor for the treatment of severe Congenital Neutropenia
Sep 23, 2019: BeyondSpring’s Plinabulin continues to build on superior product profile in breast cancer trial for neutropenia prevention
Aug 23, 2019: BeyondSpring plinabulin demonstrates superior quality of life over pegfilgrastim in a head-to-head comparison trial for the prevention of neutropenia
May 20, 2019: BeyondSpring abstract demonstrating bone pain benefit with lead asset, Plinabulin, versus Neulasta for neutropenia prevention Presented at ISPOR 2019
May 16, 2019: BeyondSpring's rationale for the plinabulin-neulasta combination for neutropenia prevention accepted as abstracts at 2019 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Neutropenia, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neutropenia – Pipeline by Akthelia Pharmaceuticals Ltd, 2022
Neutropenia – Pipeline by Aprilbio Co Ltd, 2022
Neutropenia – Pipeline by BeyondSpring Inc, 2022
Neutropenia – Pipeline by Biocon Ltd, 2022
Neutropenia – Pipeline by Biocure Technology Inc, 2022
Neutropenia – Pipeline by Biosidus SA, 2022
Neutropenia – Pipeline by Biosimilar Solutions LLC, 2022
Neutropenia – Pipeline by Cellerant Therapeutics Inc, 2022
Neutropenia – Pipeline by CPL Biologicals Pvt Ltd, 2022
Neutropenia – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd, 2022
Neutropenia – Pipeline by EmendoBio Inc, 2022
Neutropenia – Pipeline by Genova Biotech Company Ltd, 2022
Neutropenia – Pipeline by Ilkogen Ilac San Ve Tic AS, 2022
Neutropenia – Pipeline by InflaRx NV, 2022
Neutropenia – Pipeline by Lupin Ltd, 2022
Neutropenia – Pipeline by Merck & Co Inc, 2022
Neutropenia – Pipeline by Mycenax Biotech Inc, 2022
Neutropenia – Pipeline by Phoenicia Biosciences Inc, 2022
Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, 2022
Neutropenia – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Neutropenia – Pipeline by Seres Therapeutics Inc, 2022
Neutropenia – Pipeline by Shenzhen Xinpeng Bio-technology Co Ltd, 2022
Neutropenia – Pipeline by Siam Bioscience Co Ltd, 2022
Neutropenia – Pipeline by Statera Biopharma Inc, 2022
Neutropenia – Pipeline by Tanvex BioPharma Inc, 2022
Neutropenia – Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022
Neutropenia – Pipeline by USV Pvt Ltd, 2022
Neutropenia – Pipeline by X4 Pharmaceuticals Inc, 2022
Neutropenia – Dormant Projects, 2022
Neutropenia – Dormant Projects, 2022 (Contd..1)
Neutropenia – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neutropenia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022